General
Preferred name
PRINABEREL
Synonyms
WAY-202041 ()
ERB 041 ()
WAY202041 ()
ERB041 ()
ERB-041 ()
PF-00913086 ()
P&D ID
PD006361
CAS
524684-52-4
Tags
available
drug candidate
Drug indication
Crohn's disease
Inflammatory bowel disease
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Prinaberel (ERB-041) is a potent and selective estrogen receptor (ER) ¦Â agonist with IC50s of 5.4, 3.1 and 3.7 nM for human, rat and mouse ER¦Â, respectively. Prinaberel displays >200-fold selectivity for ER¦Â over ER¦Á. Prinaberel is a potent skin cancer chemopreventive agent that acts by dampening the WNT/¦Â-catenin signaling pathway. Prinaberel induces ovarian cancer apoptosis[1][2][3].
PRICE 2850
DESCRIPTION Prinaberel (ERB 041) is a selective and potent estrogen receptor ?? (ER??) agonist with anticancer activity that restores or increases ER?? expression and reduces cancer cell proliferation in mouse squamous cell carcinoma and human carcinoma cells. Prinaberel exhibits anti-inflammatory activity, inhibits the NF??B pro-inflammatory signaling pathway, and induces apoptosis of ovarian cancer cells. study endometriosis.
DESCRIPTION Prinaberel is an estrogen receptor beta (ERβ) agonist, with potential gynecological uses and antiinflammatory action .

The structure shown here matches that in the INN document for prinaberel, and as in the ChEMBL entry provided above. However, alternative tautomers are represented elsewhere including CID 5326893. (GtoPdb)
DESCRIPTION Prinaberel (ERB 041) is a selective and potent estrogen receptor β (ERβ) agonist with anticancer activity that restores or increases ERβ expression and reduces cancer cell proliferation in mouse squamous cell carcinoma and human carcinoma cells. Prinaberel exhibits anti-inflammatory activity, inhibits the NFκB pro-inflammatory signaling pathway, and induces apoptosis of ovarian cancer cells. study endometriosis. (TargetMol Bioactive Compound Library)
DESCRIPTION Tryptophan catabolite; endogenous aryl hydrocarbon receptor ligand (Tocris Bioactive Compound Library)
Compound Sets
20
Axon Medchem Screening Library
1898
Cayman Chemical Bioactives
28737
ChEMBL Drugs
CHEMBL450940
Concise Guide to Pharmacology 2017/18
6700
Concise Guide to Pharmacology 2019/20
6700
Concise Guide to Pharmacology 2021/22
6700
Concise Guide to Pharmacology 2023/24
6700
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB06832
DrugMAP
DMCEPUA
EU-OPENSCREEN Bioactive Compound Library
EOS101680
Guide to Pharmacology
6700
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL450940
Mcule NIBR MoA Box Subset
MCULE-9239598751
MedChem Express Bioactive Compound Library
HY-14933
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
TargetMol Bioactive Compound Library
TQ0149
Tocris Bioactive Compound Library
4276
External IDs
21
Properties
(calculated by RDKit )
Molecular Weight
271.06
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
3
cLogP
3.69
TPSA
66.49
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.75
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
ERβ
Wnt
Apoptosis
ESR2, NCOA1
ER-ß agonist
Estrogen Receptor/ERR
Primary Target
Estrogen and Related Receptors
MOA
Agonist
Estrogen Receptor (ER) beta Agonists
Estrogen receptor agonist
Member status
member
Pathway
Cytoskeletal Signaling
Endocrinology/Hormones
Stem Cells
Stem Cell/Wnt
Vitamin D Related/Nuclear Receptor
Source data